Extension of Haleon Licensing and Supply Agreement
Wellnex Life Limited has announced the extension of its licensing and supply agreement with Haleon UK Trading Services Ltd for soft gel liquid paracetamol products. The agreement, originally signed on March 16, 2022, has been successfully extended until March 16, 2027, continuing Wellnex Life's partnership in supplying innovative analgesic liquid soft gels for Haleon's global brands.
Select text to share a quote on X · sign in to keep highlights & notes in your WNX notes
Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") is pleased to announce that the Company, through its wholly owned subsidiary BSPS Aust Pty Ltd, has signed an extension to the existing licensing and supply agreement (the "Agreement") originally entered into on 16 March 2022 between the Company, Haleon UK Trading Services Ltd ("Haleon UK") and Olive Pharmascience Ltd. The Agreement, for the supply to Haleon UK of soft gel liquid paracetamol products, has been extended until 16 March 2027.
Eric Jiang Interim Executive Chairman said, "The Company is proud to continue its global partnership with Haleon, supporting their global brands with our innovative analgesic liquid soft gels."
This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.